Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

GLP1-RC-TZ Batch Verification

Each released GLP1-RC-TZ batch is independently analysed for chemical purity and identity, with the applicable laboratory report linked to the product batch.

New-U GLP1-RC-TZ batch evidence

Catalogue identifier: GLP1-RC-TZ

Batch number, vial count and declared mass per vial

RP-HPLC purity result for the released batch

Mass-spectrometry identity result for the released batch

Independent testing laboratory, report number and test date

Batch-linked Certificate of Analysis at /coa/tirzepatide

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Áreas de investigación publicadas

Los estudios publicados examinan actividad de receptores, farmacocinética y variables metabólicas, glucémicas y de sensibilidad a insulin definidas por protocolo. Los resúmenes siguientes informan de lo que los investigadores midieron en esos estudios externos y no constituyen instrucciones de uso para el material de investigación suministrado aquí.

Farmacología de receptores

Potencia completa en GIPR junto con señalización de GLP-1R sesgada hacia cAMP, caracterizada en estudios in-vitro publicados.

Variables metabólicas

Cambio respecto al valor basal de la masa corporal definido por protocolo, medido en todo el programa SURMOUNT.

Variables glucémicas

HbA1c como variable definida por protocolo, medida en todo el programa de diabetes SURPASS.

Variables de sensibilidad a insulin

Marcadores de sensibilidad a insulin y adiponectin, medidos junto con señalización adiposa directa mediada por GIPR.

Farmacocinética

Exposición sistémica, biodisponibilidad y semivida aparente, a partir de la caracterización farmacocinética publicada.

Overview

In short: GLP1-RC-TZ es un compuesto de investigación agonista dual de GIPR / GLP-1R, denominado habitualmente “Tirz” en comunidades de investigación.

Key research facts

Farmacología de receptores: actividad agonista dual GIPR / GLP-1R caracterizada en estudios in-vitro publicados

Se ha comunicado agonismo desequilibrado: potencia completa de GIPR con señalización de GLP-1R sesgada hacia cAMP frente al reclutamiento de β-arrestin

Sustituciones Aib2 y Aib13 investigadas por su resistencia a DPP-IV y proteasas

Se ha comunicado que la modificación C20 fatty-diacid proporciona una unión a albúmina del 99%; la semivida aparente de eliminación comunicada es de ~5 días

RCT SURMOUNT-1 (NEJM 2022, PMID 35658024), brazo de 15 mg: los investigadores comunicaron un cambio medio de −20.9% respecto al valor basal en el peso corporal en la semana 72

These points summarise lab themes, not human outcomes.

Los trabajos publicados caracterizan la farmacología de receptores, las modificaciones estructurales y el perfil farmacocinético de esta clase de compuestos, junto con variables definidas por protocolo investigadas en programas clínicos registrados.

La verificación de lotes de New-U y la literatura externa son conjuntos de evidencia independientes: los análisis del lote establecen la identidad analítica y la pureza del material analizado; los estudios publicados describen sus propios materiales y protocolos de investigación.

Read the full scientific overview

Arquitectura molecular

LY3298176 es un péptido sintético de 39 aminoácidos caracterizado en estudios de farmacología de receptores como agonista de dos incretin receptors, GLP-1R y GIPR, en lugar de GLP-1R solo.

Farmacología de receptores

La literatura describe el perfil como desequilibrado: potencia completa en GIPR superpuesta a una señal GLP-1R sesgada hacia cAMP. Tabla completa de vías: Receptor Pharmacology a continuación.

Modificaciones estructurales

Los trabajos estructurales publicados describen sustituciones Aib2 y Aib13 investigadas para resistencia a proteasas y un C20 fatty diacid unido a Lys20 mediante un espaciador γGlu/AEEA, investigado como contribuyente de unión a albúmina a una exposición sistémica prolongada.

Farmacocinética publicada

La semivida aparente de eliminación se sitúa en aproximadamente cinco días, con alrededor del 80% de biodisponibilidad subcutánea. Perfil completo: Pharmacokinetics a continuación.

Investigación clínica

Los hallazgos publicados resumidos en esta página se refieren a estudios clínicos externos del medicamento de referencia y a sus respectivos materiales y protocolos. No establecen la seguridad, eficacia ni equivalencia clínica del material GLP1-RC-TZ de New-U.

Referencias principales

Las publicaciones revisadas por pares y los registros de ensayos clínicos registrados se enumeran íntegramente, con identificadores DOI/PMID/NCT, en Source References a continuación.

Receptor Pharmacology

Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GIPR Full agonist activity characterised experimentally, comparable to native GIP The arm that distinguishes the dual agonist from single GLP-1R compounds in the literature GLP-1R Agonist activity characterised as biased, favouring cAMP signalling over β-arrestin recruitment Investigated in relation to receptor desensitisation over prolonged exposure Adipose GIPR signalling Direct GIPR-mediated adipose effects characterised experimentally Investigated as a contributor to measured insulin-sensitivity markers and adiponectin Albumin-binding modification C20 eicosanedioic acid via a γGlu/AEEA spacer; 99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~5-day apparent half-life) Proteolytic stability Aib2 and Aib13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and proteases

Deeper dive for scientific readers

The imbalanced-agonism profile is characterised in JCI Insight (2020): full GIPR potency layered onto a cAMP-biased GLP-1R signal. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024) investigators reported a mean change from baseline in body weight of −20.9% at week 72 in the 15 mg arm. SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) was designed as a head-to-head comparison against semaglutide and reported −20.2% vs −13.7% at week 72. SURPASS-CVOT (NEJM 2025) compared cardiovascular outcomes against dulaglutide and reported an approximately 8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality. Insulin-sensitivity improvements beyond what change in body weight alone accounts for are discussed in the literature as consistent with direct GIPR-mediated adipose effects. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

¿Qué es Tirzepatide en investigación científica?

Tirzepatide (LY3298176) es un péptido sintético de 39 aminoácidos caracterizado en estudios de farmacología de receptores como agonista dual de los receptores GIP / GLP-1 con agonismo desequilibrado. Está aprobado como medicamento en algunas jurisdicciones bajo marcas de otros fabricantes; el material suministrado aquí no es ese producto farmacéutico terminado.

¿Qué es GLP1-RC-TZ?

GLP1-RC-TZ es el identificador de catálogo de New-U para el material de investigación de laboratorio ofrecido mediante este perfil de investigación. No es un medicamento, un tratamiento, un producto farmacéutico genérico ni un producto terapéutico, no es equivalente a ningún producto clínico o comercial y no se ofrece para uso humano ni veterinario.

¿Qué sistemas receptores se estudian en la investigación sobre Tirzepatide?

La farmacología in-vitro publicada caracteriza dos receptores: GIPR, donde la potencia agonista se comunica como comparable a GIP nativo, y GLP-1R, donde se comunica una señalización sesgada hacia la generación de cAMP frente al reclutamiento de β-arrestin. Los trabajos estructurales investigan además la modificación C20 fatty-diacid de unión a albúmina y las sustituciones Aib2/Aib13 para modificar la estabilidad proteolítica.

¿Qué análisis analíticos acompañan a GLP1-RC-TZ?

Cada lote liberado de GLP1-RC-TZ se analiza en un laboratorio analítico independiente para determinar la pureza mediante normalización de área RP-HPLC y la identidad mediante espectrometría de masas, y el resultado se publica como Certificate of Analysis vinculado al lote, registrando el laboratorio, el número de informe, la pureza medida y la fecha del análisis. El análisis del lote informa sobre identidad y pureza de la muestra analizada. No establece esterilidad, estado de endotoxinas o metales pesados, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Dónde puedo consultar el COA del lote actual de GLP1-RC-TZ?

El certificado del lote actual, con laboratorio, número de informe, pureza medida y fecha de análisis, se publica en /coa/tirzepatide junto con el historial de análisis del compuesto.

¿Qué significa una pureza HPLC >99%?

Es una cifra de pureza obtenida mediante reversed-phase high-performance liquid chromatography utilizando normalización de área: el pico objetivo representa más del 99% del área total integrada de picos del cromatograma de la muestra analizada. Es una afirmación únicamente sobre la pureza química de esa muestra y no dice nada sobre esterilidad, contenido de endotoxinas, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Qué ensayos clínicos se citan en esta página?

Tres estudios externos del medicamento de referencia: SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) y SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), junto con la caracterización de farmacología de receptores en JCI Insight (2020). Cada resultado comunicado en esta página se atribuye a su estudio, brazo y momento temporal.

¿Cómo se distingue la investigación clínica publicada de los análisis de lotes de New-U?

Son conjuntos de evidencia separados. La investigación clínica publicada es trabajo externo sobre el producto farmacéutico terminado aprobado, realizado según los propios protocolos de esos estudios; no establece nada sobre el material suministrado aquí. Los análisis de lotes de New-U son trabajos analíticos sobre el propio lote GLP1-RC-TZ, pureza RP-HPLC e identidad por espectrometría de masas, y no establecen nada clínico. Un certificado de análisis combinado con un artículo clínico externo no equivale a validación clínica de GLP1-RC-TZ.

¿Es GLP1-RC-TZ lo mismo que un medicamento de marca aprobado?

No. Los productos de marca aprobados de tirzepatide son productos farmacéuticos terminados estériles con receta, fabricados bajo cGMP por su titular de autorización de comercialización. GLP1-RC-TZ es material de investigación de laboratorio no aprobado suministrado como polvo liofilizado. No es equivalente, genérico ni sustituto de ningún producto aprobado.

¿Por qué Tirzepatide se describe como desequilibrado en la literatura?

Porque los dos brazos receptores no están equilibrados: la farmacología publicada comunica una potencia de agonista completo en GIPR comparable a GIP nativo, pero una señalización sesgada en GLP-1R que favorece la generación de cAMP frente al reclutamiento de β-arrestin. La literatura investiga esta asimetría en relación con la desensibilización del receptor durante exposiciones prolongadas.

¿En qué se diferencia la investigación sobre Tirzepatide de la investigación sobre Retatrutide y Semaglutide?

Según la cobertura de receptores caracterizada en la literatura: la investigación sobre semaglutide describe agonismo de GLP-1R, la investigación sobre tirzepatide describe agonismo de GIPR/GLP-1R y la investigación sobre retatrutide estudia agonismo de GLP-1R/GIPR/GCGR. Solo SURMOUNT-5 fue diseñado como comparación directa (tirzepatide vs semaglutide); los resultados obtenidos de programas independientes no son comparaciones directas.

¿En qué forma se suministra GLP1-RC-TZ?

GLP1-RC-TZ se suministra como polvo liofilizado en viales sellados, en paquetes de investigación sellados de 10 viales en las concentraciones indicadas, con un Certificate of Analysis vinculado al lote.

¿Cómo debe almacenarse el material de investigación de laboratorio?

Conservar el polvo liofilizado en un congelador a −20 °C. Si un protocolo de laboratorio requiere el material en solución, mantener la solución resultante refrigerada a 1–6 °C, protegida de la luz y evitar ciclos repetidos de congelación-descongelación, que pueden degradar la modificación de fatty-acid. Las condiciones de almacenamiento son únicamente información de manipulación de laboratorio.

Is it legal to buy Tirzepatide?

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 8–72 h Bioavailability ~80% subcutaneous reported Metabolism / clearance Proteolytic backbone cleavage, β-oxidation of the C20 fatty-diacid chain and amide hydrolysis reported; metabolites eliminated ~66% renally / ~33% faecally; no CYP-mediated interactions Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~10.3 L; 99% albumin-bound. These are pharmacokinetic observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

SURMOUNT-1 RCT (Jastreboff et al., NEJM 2022; PMID 35658024), obesity/overweight population, 15 mg arm: investigators reported a mean change from baseline in body weight of −20.9% at week 72

SURMOUNT-5 head-to-head RCT (Aronne et al., NEJM 2025; PMID 40353578): investigators reported −20.2% in the tirzepatide arm vs −13.7% in the semaglutide arm at week 72

SURPASS-CVOT RCT (NEJM 2025), 13,000+ participants vs dulaglutide: investigators reported an ~8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality

SURPASS diabetes programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Insulin-sensitivity markers and adiponectin recorded as measured endpoints, discussed in the literature in relation to direct GIPR-mediated adipose signalling

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The SURPASS and SURMOUNT programmes included 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg arms, with a protocol-defined step-up period of roughly 20 weeks before the maintenance arm level was reached. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite and dyspepsia recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Hypersensitivity and injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Tier 1 · Human clinical

SURMOUNT-1 obesity RCT — −20.9% mean change from baseline in body weight at week 72 (NEJM 2022; PMID 35658024)

SURMOUNT-5 head-to-head RCT vs semaglutide — −20.2% vs −13.7% at week 72 (NEJM 2025; PMID 40353578)

SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. · 2022 · PMID: 35658024 · DOI: 10.1056/NEJMoa2206038

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2505928

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

39-amino-acid synthetic peptide built on the GIP backbone (LY3298176)

Dual GIPR / GLP-1R agonist activity characterised with imbalanced agonism

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding

Apparent elimination half-life reported at approximately 5 days in published pharmacokinetic research

GLP1-RC-TZ laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

Identificador de catálogo de New-U GLP1-RC-TZ Objeto científico Tirzepatide (LY3298176) Peso molecular 4,813.53 Da Receptores caracterizados GIPR (agonista completo), GLP-1R (sesgado hacia cAMP) Pureza (analítica) >99% por normalización de área RP-HPLC Identidad (analítica) Confirmado mediante espectrometría de masas en el lote liberado Forma Polvo liofilizado Semivida publicada Aproximadamente 5 días, media de 116.7 h (investigación farmacocinética externa) Conservación Liofilizado: congelador a −20 °C. Reconstituido: 1-6 °C, protegido de la luz. Uso previsto Laboratory research material. Not for human or veterinary use.

Tirzepatide Research — GLP1-RC-TZ Laboratory Research Material

Tirzepatide is the most extensively characterised dual-incretin ("twincretin") peptide in the published literature. Receptor-pharmacology studies describe full GIPR agonist potency layered onto a cAMP-biased GLP-1R signal, and the clinical programme includes one trial, SURMOUNT-5 (NEJM 2025), specifically designed as a head-to-head comparison against semaglutide.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −20.9% at week 72 in the SURMOUNT-1 15 mg arm (NEJM 2022), −20.2% vs −13.7% against semaglutide at week 72 in SURMOUNT-5 (NEJM 2025), an ~8% relative reduction in major adverse cardiovascular events against dulaglutide in SURPASS-CVOT (NEJM 2025), and HbA1c reductions of up to 2.58% in the SURPASS programme. Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-TZ as lyophilised, analytically verified laboratory research material at >99% HPLC purity, with identity and purity confirmed by independent laboratories. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material. GLP1-RC-TZ is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Tirzepatide vs related Metabolic Research compounds

Compound Price Purity spec COA Tirzepatide from $168 >99% HPLC 2 published batches Retatrutide from $210 >99% HPLC 4 published batches Semaglutide from $158 >99% HPLC 1 published batch

Tirzepatide vs Retatrutide - full comparison

Tirzepatide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tirzepatide

Metabolic Research research compounds

Tirzepatide research guide

Tirzepatide pricing and packs

Research this compound

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Compare Compare Tirzepatide and Retatrutide Tirzepatide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Tirzepatide COA Current batch purity and identity testing, 2026-05-27. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research